Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-126-0 | CAS number: 78-59-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute toxicity in laboratory animals is low to moderate (oral LD50 = 1500 mg/kg bw; dermal LD50 = 1200 mg/kg bw; inhalative LC50 = 7000 mg/m3).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Voss
- Weight at study initiation: 80 - 115 g - Route of administration:
- oral: unspecified
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 0.5 % CMC - Doses:
- 500; 1000; 1250; 1500; 1750; 2000; 2500 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 13 days
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs, other: gross examination of: coat of fur, skin, eye and conjunctiva, nose, mouth, ear, anus, preputial opening, vulva, subcutaneous connective tissue, abdominal cavity, pelvic cavity, peritoneum, esophagus, stomach, small intestine, large intestine, mesenteric lymph nodes, liver, pancreas, spleen, kidneys, urinary bladder, seminal vesicle, prostate, testicles, epididymis, ovary, uterus, vagina, thoracic cavity, pleura, heart, lungs, trachea, thymus gland, cerebrum, middle ear, application sites - Statistics:
- Probit analysis
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 500 mg/kg bw
- 95% CL:
- 1 400 - 1 800
- Mortality:
- Time to death: 1 hour to 3 days after dosing
Number of deaths at each dose:
500 mg/kg: 0/10
1000 mg/kg: 1/10
1250 mg/kg: 1/10
1500 mg/kg: 5/10
1750 mg/kg: 7/10
2000 mg/kg: 10/10
2500 mg/kg: 8/10 - Clinical signs:
- other: > 1000 mg/kg: general apathy, lateral position, irregular respiration
- Gross pathology:
- Necropsy findings (results of animals that died): increased secretion in stomach and small intestine; thickening and hemorrhagic erosions of proventriculus lining; urine retention; hyperemia of liver; pulmonary emphysema, edema, or hyperemia; splenic enlargement
- Interpretation of results:
- Category 4 based on GHS criteria
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 500 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 200-225 g
- Housing: wire mesh cages - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: dynami stainless steel exposure chamber
- Exposure chamber volume: 500 L
- Method of holding animals in test chamber: caged
- System of generating vapors: by means of metering predetermined amounts of the liquid material by a precision metering pump into a stainless steel spray nozzle tip operating under positive air pressure. The material metered through the nozzle were then vaporized by the pressurized air flow directly in the exposure chamber
TEST ATMOSPHERE
- Brief description of analytical method used: nominal dosage concentrations were calculated from the amount of liquid being metered and the total airflow through the chamber. - Analytical verification of test atmosphere concentrations:
- no
- Duration of exposure:
- 4 h
- Concentrations:
- 5; 7; 10; 17.8 mg/l
- No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: during exposure at 30 min intervals, following exposure once daily
- Necropsy of survivors performed: yes - Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- 7 mg/L air
- 95% CL:
- >= 5.7 - <= 8.6
- Exp. duration:
- 4 h
- Mortality:
- Dose Mortality
[mg/L] 4 hours 14 days
------------------------------------
5 0/10 1/10
7 0/10 4/10
10 10/10 10/10
17.8 10/10 10/10 - Clinical signs:
- other: see "Other findings"
- Gross pathology:
- Autopsies of animals that died during exposure and those that survived revealed varying degrees of pulmonary congestion (slight to marked).
- Other findings:
- During exposure, the animals exposed to the lowest dose level (5 mg/L) showed no effects while those at the higher levels became ataxic and comatose towards the end of the 4-hour exposure period. Following exposure, the surviving animals at the lowest level appeared normal while those at the other levels demonstrated dyspnea, piloerection, depression, and decreased activity.
- Interpretation of results:
- GHS criteria not met
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 7 000 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rabbit
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: ca 2.5 kg - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- REMOVAL OF TEST SUBSTANCE
- Time after start of exposure: after 24 hours, unresorbed quantity determined - Duration of exposure:
- 24 hours
- Doses:
- 9200; 13850; 23000; 23000; 32300 mg
- No. of animals per sex per dose:
- 6
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: daily - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 200 mg/kg bw
- Remarks on result:
- other: according to the authors, as cited in OECD SIDS
- Mortality:
- Number of deaths and time at each dose:
9.2 g dose (0.6 ± 0.4 g/kg absorbed): none
13.85 g dose (0.75 ± 0.5 g/kg): 2 after 6 and 12 hours, resp.
23 g dose (1.7 ± 0.9 g/kg): 3 after 3, 4, and 5 hours, resp.
23 g dose (2.85 ± 1.3 g/kg): 3 after 4, 6, and 48 hours, resp.
32.3 g dose (2.5 ± 1 g/kg): 6 after 2.5, 4x4, 5 hours, resp. - Clinical signs:
- other: Accelerated breathing, prostration, narcosis, death (mostly within 6 hours) or recovery. The intensity of the erythema varied between animals. Recovery of the skin was not always complete within the postexposure period. Doses at which clinical signs appea
- Interpretation of results:
- Category 4 based on GHS criteria
Reference
MORTALITY
Dose absorbed deaths timepoint
[mg] [mg/kg] [hours]
---------------------------------------------------
9200 600 ± 400 0/6 -
13850 750 ± 500 2/6 6, 12
23000 1700 ± 900 3/6 3, 4, 5
23000 2850 ± 1300 3/6 4, 6, 48
32300 2500 ± 1000 6/6 2.5, 4 x 4, 5
LD50: 1200 mg/kg bw (according to OECD SIDS)
CLINICAL SIGNS
Animals showed accelerated breathing, prostration and narcosis.
Death occured mostly within 6 hours, but survivors recovered.
The intensity of the erythema varied between animals, recovery of the skin was not always complete within the postexposure period.
Doses at which clinical signs appeared were not defined in the study.
POTENTIAL TARGET ORGANS
None identified (except skin).
SEX-SPECIFIC DIFFERENCES
None identified.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 200 mg/kg bw
Additional information
Oral toxicity
LD50 values of isophorone in rats were 1500 mg/kg bw (Schering, 1968), 2100 mg/kg bw (Dutertre-Catella, 1976) and 3450 mg/kg bw (Esso Research, 1964) The LD50 in mice is 2200 mg/kg bw (Dutertre-Catella, 1976). Clinical signs like general apathy, depression, weariness (leading to coma) ptosis, lacrimation and laboured respiration occurred at doses of ≥ 1450 mg/kg bw (Schering, 1968; Dutertre-Catella, 1976; Esso Research, 1964). At doses of ≥ 5000 mg/kg bw congestion of lungs, kidneys and pancreas (Esso Research, 1964) and liver lesions (Dutertre-Catella, 1976) were found at necropsy.
Inhalation toxicity
In acute inhalation studies isophorone showed very low acute toxicity with LC50 values sometimes exceeding the maximal vapour concentration of 2.3 mg/l. A LC50 value of 7000 mg isophorone/m3 (aerosol) was determined in rats (Esso Research, 1965). Mortality was observed in another study with rats but not guinea pigs at concentrations ≥ 10,570 mg/m3 (Smyth, 1940). Clinical signs were nose and eye irritation, accelerated, laboured respiration, intestinal peristalsis and coma at dose ≥ 5000 mg/m3 (Smyth, 1940; Esso Research, 1965). At necropsy of the high exposure concentrations, congestion of the lungs and occasionally observed liver and stomach congestion was found (Esso Research, 1965; Smyth, 1940).
Signs of respiratory tract irritation were also seen in humans (workers and volunteers) exposed to the test substance by inhalation (IUCLID chapter 7.10).
Dermal toxicity
For rabbits the LD50 values were 1200 mg/kg bw (Dutertre-Catella, 1976) and > 3160 mg/kg bw (Esso Research, 1965). In rats, the LD50 after dermal application was 1700 mg/kg bw (Schering, 1968).
Clinical signs were general apathy, later on occasionally coma, cachexia, tremor, lacrimation (Schering, 1968) and depression, accelerated/laboured respiration, sprawling, prostration and narcosis at doses of 3160 mg/kg bw at least. At necropsy uniform thickening of the cutaneous stomach mucosa and pulmonary emphysema, edema or hyperemia was observed.
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is considered to be classified for acute oral and dermal toxicity as cat. 4, H302 and H312, and respiratory tract irritation STOT SE cat. 3, H335 under Regulation (EC) No. 1272/2008, as amended for the 14th time in Regulation (EU) 2020/217.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.